FDMT Q2 2021 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$427M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+301.3% YoY

Gross Profit

-$643,000-4.4% margin

Operating Income

-$8M-52.1% margin

Net Income

-$8M-52.1% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

+629.0%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$17M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$255M

Total Liabilities

$14M

Stockholders' Equity

$241M

Cash & Equivalents

$244M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$4M	+301.3%
Gross Profit	-$643,000	-$12M	+94.7%
Operating Income	-$8M	-$15M	+49.9%
Net Income	-$8M	-$15M	+49.9%

Geographic Segments

SWITZERLAND

$14M98%

NETHERLANDS

$267,0002%

UNITED STATES

$16,0000%